Sarepta reports early SRP-1003 data that match preclinical results and show dose-dependent exposure, while a rival Phase 3 miss raises questions, so the report does not change Sarepta’s outlook.
Sarepta reported encouraging early SRP-1003 data showing dose-dependent drug exposure and no uptake saturation. Novartis’ Phase 3 missed its DM1 primary endpoint, raising questions about the clinical measure. These facts point different ways, so the story leaves Sarepta unchanged.
Novartis’ Phase 3 HARBOR study did not meet its primary endpoint for DM1, which is a setback for the program.
Follow Sarepta Therapeutics Inc. (SRPT) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for SRPT